According to a recent market report published by Transparency Market Research, the global platelet rich plasma (PRP) market is estimated to experience a compound annual growth rate of 11.9% from 2014 to 2020, reaching a value of 0.35 Billion by the end of this period.
The study divided the PRP market by PRP types, origin, applications, and geography.
The three types of PRP treatments considered in the market study were:
- Pure-Platelet Rich Plasma (P-PRP)
- Leukocyte-Platelet Rich Plasma (L-PRP)
- Leukocyte-Platelet Rich Fibrin (L-PRF)
Pure-Platelet Rich Plasma (P-PRP) is characterized by having a high concentration of platelets and growth factors – this is considered the “conventional” PRP therapy, which currently holds more than 60% of the global market.
Leukocyte-Platelet Rich Fibrin (L-PRF) is a newer type of PRP therapy which includes a high number of white blood cells, known as leukocytes. L-PRF is anticipated to be the segment with the fastest growth from 2014 to 2020.
When classified by the origin, there are three PRP market segments:
From these, the current largest market belongs to the Autologous PRP segment, which is the type of PRP that is obtained from the same patient who will receive the PRP treatment. Since autologous PRP is derived from the own patient’s blood, it is easy to obtain and it eliminates the possibility of an immune rejection. According to the market study, the allogenic PRP is expected to grow significantly within the next years.
PRP therapy has several applications, including:
- Orthopedic Surgery
- Cosmetic Surgery
- General Surgery
- Other Surgeries
Orthopedic surgery is currently the largest application segment with more than 30% of the global PRP market. The efficacy of PRP in the treatment of orthopedic and sports injuries and the growing geriatric population in developed and developing countries, explain why this is the largest application segment of PRP therapy. The cosmetic applications are expected to grow significantly by 2020.
The Geographic segmentation of the PRP market is as follows:
- North America
- Rest of the World
Currently, North America is the largest geographical PRP market segment due to the increasing number of cosmetic and orthopedic procedures performed in the region, as well, the growing awareness about the efficacy of PRP therapy. The Asia-Pacific PRP market segment is expected to witness a strong growth during the upcoming years.
Platelet rich plasma (PRP) therapy is a novel and promising type of regenerative medicine treatment that has proven to be effective in the treatment of athletes’ sports injuries such as tennis elbow. But athletes are not the only ones who can benefit from PRP therapy, sports horses have been successfully treated as well.
According to the University of California, Davis, all horses are prone to developing tendon and ligament injuries, regardless of their breed and function, however, athletic horses are at a greater risk.
Tendon and ligament injuries in horses are characterized by having a very slow healing rate and a high rate of recurrence. Serious injuries usually require difficult and expensive treatment and may, in some cases, end with the sporting career of a horse.
Until recently, tendon and ligament injuries in horses had been managed with palliative treatments that do not stimulate tissue healing. The recent advancements in regenerative medicine, both in humans and animals, have opened a new treatment possibility for racing horses.
The main advantage of PRP therapy is that it may lead to tissue regeneration and healing, in other words, PRP stimulates the body to heal the injured tendon or ligament.
According to Dr. Larry D. Galuppo, a veterinarian and horse surgery specialist, PRP therapy can improve the healing process in horses and reduce the chances for re-injury after the horses have returned to their typical activities.
The Case of Aidan the Horse
The Veterinary Medical Teaching Hospital of the University of California, Davis published the case study of a sporting horse named Aidan.
Aidan presented to the hospital for being lame on his right forelimb during 10 days. After a thorough physical examination and various diagnostic procedures, including an ultrasound of the lame limb, Aidan was diagnosed with an injury of the collateral ligament injury of the right limb.
Aidan was treated with PRP therapy and anti-inflammatories, and he was in rehabilitation during 6 months. Aidan’s signs of lameness began to improve 30 days after he received the first PRP injection. The lameness signs continued to improve through the months with constant rehabilitation therapy and Aidan was able to return to his normal activities.
Aidan’s positive response to PRP therapy shows that this is a promising therapy for athletic horses, that could help valuable horses return to their normal functions.
University of California, Davis. School of Veterinary Medicine. Platelet-Rich Plasma: Improving Treatment for Tendon and Ligament Injuries. (2011). The horse Report. Volume 29.
FIND OUT MORE ABOUT CLINICAL APPLICATION OF PRP THERAPY